8082-737-676
Kalkine 0
countryflagUK
Logi

0R15 7172.0 -4.284% 0R1E 10080.0 -3.263% 0M69 None None% 0R2V 206.0 -8.2814% 0QYR 1608.0 -7.4266% 0QYP 374.2 -2.1699% 0RUK None None% 0RYA 1551.0 -2.2684% 0RIH 156.5 -0.5402% 0RIH 152.0 -2.8754% 0R1O 180.2 9265.9044% 0R1O None None% 0QFP 10450.0 107.3413% 0M2Z 279.7562 -0.1879% 0VSO 44.63 25.3476% 0R1I None None% 0QZI 587.0 0.8591% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 158.85 -6.9129%
0R15 7172.0 -4.284% 0R1E 10080.0 -3.263% 0M69 None None% 0R2V 206.0 -8.2814% 0QYR 1608.0 -7.4266% 0QYP 374.2 -2.1699% 0RUK None None% 0RYA 1551.0 -2.2684% 0RIH 156.5 -0.5402% 0RIH 152.0 -2.8754% 0R1O 180.2 9265.9044% 0R1O None None% 0QFP 10450.0 107.3413% 0M2Z 279.7562 -0.1879% 0VSO 44.63 25.3476% 0R1I None None% 0QZI 587.0 0.8591% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 158.85 -6.9129%

Cencora Inc.

Healthcare US COR

287.31USD
7.80(2.79%)

Last update at 2025-04-03T16:45:00Z

Day Range

280.03289.60
LowHigh

52 Week Range

146.29205.83
LowHigh

Fundamentals

  • Previous Close 279.51
  • Market Cap38515.76M
  • Volume1168768
  • P/E Ratio23.39
  • Dividend Yield1.04%
  • EBITDA3418.52M
  • Revenue TTM254425.24M
  • Revenue Per Share TTM1247.29
  • Gross Profit TTM 8334.57M
  • Diluted EPS TTM8.20

Analyst Recommendations

Financials

Income Statement

2019-09-302020-09-302021-09-302022-09-302023-09-300M20000M40000M60000M80000M100000M120000M140000M160000M180000M200000M220000M240000M260000M
Total Revenue
Net Income

Balancesheet

2019-09-302020-09-302021-09-302022-09-302023-09-300M5000M10000M15000M20000M25000M30000M35000M40000M45000M50000M55000M60000M
Total Assets
Total Liabilities

Change in Cash

2019-09-302020-09-302021-09-302022-09-302023-09-30-1400M-1200M-1000M-800M-600M-400M-200M0M200M400M600M800M1000M1200M

Total Operating Cash

2019-09-302020-09-302021-09-302022-09-302023-09-302200M2400M2600M2800M3000M3200M3400M3600M3800M4000M

Dividends Paid

2019-09-302020-09-302021-09-302022-09-302023-09-30-300M-200M-100M0M100M200M300M
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Income before tax 2160.84M 2183.06M 2221.86M -5293.83100M 967.11M
Minority interest 12.72M 32.28M -4.67600M -9.15800M 1.23M
Net income 1745.29M 1698.82M 1539.93M -3408.71600M 855.37M
Selling general administrative 5309.98M 4848.96M 3594.25M 80.57M 76.39M
Selling and marketing expenses - - - 23.73M 2663.51M
Gross profit 8959.49M 8334.57M 6774.43M 5195.36M 5138.31M
Reconciled depreciation 963.90M 693.89M 514.79M 391.06M 462.41M
Ebit 2734.64M 2780.86M 2894.01M 2035.19M 2025.35M
Ebitda 3698.55M 3474.76M 3408.80M 2426.25M 2487.76M
Depreciation and amortization 963.90M 693.89M 514.79M 391.06M 462.41M
Non operating income net other - - - - -
Operating income 2340.73M 2366.38M 2354.20M -5135.35400M 1111.92M
Other operating expenses 259487.81M 235833.50M 211145.04M 187860.32M 177576.72M
Interest expense 228.93M 210.67M 182.54M 137.88M 157.77M
Tax provision 428.26M 516.52M 677.25M -1894.27300M 112.97M
Interest income 228.93M 21.31M 8.47M 20.64M 37.70M
Net interest income -228.93100M -210.67300M -174.07400M -137.88300M -157.76900M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 428.26M 516.52M 677.25M -1894.27300M 112.97M
Total revenue 262173.41M 238587.01M 213988.84M 189893.93M 179589.12M
Total operating expenses 6273.89M 5542.86M 4099.42M 3158.28M 3125.91M
Cost of revenue 253213.92M 230252.44M 207214.41M 184698.56M 174450.81M
Total other income expense net -295.83800M -359.78000M -447.87200M -7189.55300M -887.52200M
Discontinued operations - - - - -
Net income from continuing ops 1732.58M 1666.54M 1544.61M -3399.55800M 854.13M
Net income applicable to common shares 1745.29M 1698.82M 1539.93M -3408.71600M 855.37M
Preferred stock and other adjustments - - - - -
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Total assets 62558.75M 56560.62M 57337.81M 43947.86M 39171.98M
Intangible assets 14005.90M 4332.74M 5256.93M 1886.11M 2294.84M
Earning assets - - - - -
Other current assets 1840.93M 2192.50M 2125.16M 1533.95M 1310.73M
Total liab 61892.46M 56489.34M 56753.39M 44787.50M 36178.77M
Total stockholder equity 666.29M -289.78400M 223.35M -839.63600M 2993.21M
Deferred long term liab - - - - -
Other current liab 2353.82M 2214.59M 192.07M 1593.61M 1057.21M
Common stock 666.29M 2.93M 2.91M 2.88M 2.85M
Capital stock - 2.93M 2.91M 2.88M 2.85M
Retained earnings - 2977.65M 1670.51M 518.34M 4235.49M
Other liab - 7514.74M 8064.89M 7257.62M 2243.08M
Good will - 8503.89M 9030.53M 6706.72M 6705.51M
Other assets 3618.85M 1054.26M 1017.60M 697.97M 269.07M
Cash 2592.05M 3388.19M 2547.14M 4597.75M 3374.19M
Cash and equivalents 2592.05M 3388.19M 2547.14M 4597.75M -
Total current liabilities 48831.20M 43477.96M 41358.64M 33853.08M 29581.29M
Current deferred revenue -641.34400M - 2856.41M 53.15M -
Net debt 2195.41M 2314.64M 4136.78M -478.22600M 798.70M
Short term debt 641.34M 1070.47M 300.21M 501.26M 139.01M
Short long term debt 641.34M 1070.47M 300.21M 501.26M 139.01M
Short long term debt total 4787.46M 5702.83M 6683.92M 4119.52M 4172.89M
Other stockholder equity 666.29M -1439.38700M -1004.62400M -1252.01900M -1133.17300M
Property plant equipment 2135.17M 3079.98M 3230.14M 1928.33M 1770.52M
Total current assets 42798.83M 39589.76M 38802.61M 33019.85M 28132.05M
Long term investments - - - - -
Net tangible assets - -13048.18200M -14064.10400M -9611.75000M -6121.42600M
Short term investments - 0.00000M 372.91M - -
Net receivables 20911.08M 18452.67M 18389.05M 14298.88M 12386.88M
Long term debt 4146.11M 4632.36M 6383.71M 3618.26M 4033.88M
Inventory 17454.77M 15556.39M 15368.35M 12589.28M 11060.25M
Accounts payable 45836.04M 40192.89M 38009.95M 31705.06M 28385.07M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - -1830.97000M -445.44200M -108.83000M -111.96500M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3418.18M 1761.66M 1793.99M 779.85M 269.07M
Deferred long term asset charges - - - - -
Non current assets total 19759.92M 16970.86M 18535.20M 10928.01M 11039.93M
Capital lease obligations - - - - -
Long term debt total 4146.11M 4632.36M 6383.71M 3618.26M -
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Investments -2602.46500M -368.43700M -6141.57700M -379.87100M -375.83200M
Change to liabilities - 3320.72M 2049.17M 3300.83M 1561.05M
Total cashflows from investing activities -2602.46500M -368.43700M -6141.57700M -379.87100M -375.83200M
Net borrowings - -923.10300M 2216.55M -32.00600M -133.07300M
Total cash from financing activities -2222.27800M -1752.78000M 1952.85M -603.61700M -1086.51300M
Change to operating activities - -854.72000M 276.14M 6751.01M 234.22M
Net income 1732.58M 1666.54M 1544.61M -3399.55800M 854.13M
Change in cash -840.65000M 523.41M -1527.61800M 1223.55M 881.68M
Begin period cash flow 3593.54M 3070.13M 4597.75M 3374.19M 2492.52M
End period cash flow 2752.89M 3593.54M 3070.13M 4597.75M 3374.19M
Total cash from operating activities 3911.33M 2703.09M 2666.59M 2207.04M 2344.02M
Issuance of capital stock - 0.00000M 0.00000M 66.36M -
Depreciation 963.90M 709.84M 514.79M 408.01M 497.51M
Other cashflows from investing activities -2144.10600M 127.88M -5703.36000M -10.19400M -2.95400M
Dividends paid -398.75200M -391.68700M -366.64800M -343.57800M 338.97M
Change to inventory -2183.36800M -665.37000M -1116.34400M -1621.14300M -167.99000M
Change to account receivables -2711.78600M -1659.52500M -930.07800M -1628.99100M -1241.89000M
Sale purchase of stock -1180.72800M -483.70400M -82.15000M -420.44900M -674.03100M
Other cashflows from financing activities -19.54000M -48.19800M -13.65500M 126.06M -16.66900M
Change to netincome - 434.10M 244.55M -1061.28500M 621.95M
Capital expenditures 458.36M 496.32M 438.22M 369.68M 310.22M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 874.54M -139.66200M 367.32M 6664.40M 363.38M
Stock based compensation - 93.40M 99.59M 74.41M 58.87M
Other non cash items 340.31M 176.79M -194.59000M 4.75M 541.59M
Free cash flow 3452.97M 2206.77M 2228.37M 1837.36M 2033.80M

Peer Comparison

Sector: Healthcare Industry: Medical Distribution

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
COR
Cencora Inc.		 7.80 2.79% 287.31 23.39 - - -
MCK
McKesson Corporation		 20.96 3.02% 714.49 17.95 14.53 0.20 5.04 0.22 12.17
CAH
Cardinal Health Inc		 -2.55 1.84% 136.12 166.11 14.71 0.12 16.07 0.12 19.78
HSIC
Henry Schein Inc		 -2.05 2.96% 67.20 24.12 14.04 0.74 2.50 0.95 13.33
SHPMF
Shanghai Pharmaceuticals Holding Co. Ltd		 - -% 1.56 7.71 5.45 0.03 0.57 0.03 0.88

Reports Covered

Stock Research & News

View All

Profile

Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

Cencora Inc.

1 West First Avenue, Conshohocken, PA, United States, 19428-1800

Key Executives

Name Title Year Born
Mr. Steven H. Collis Chairman, Pres & CEO 1961
Mr. James F. Cleary Jr. Exec. VP & CFO 1963
Dr. Robert P. Mauch Ph.D., PharmD Exec. VP & COO 1967
Ms. Gina K. Clark Exec. VP and Chief Communications & Admin. Officer 1957
Mr. John G. Chou Exec. VP and Special Advisor to the Chairman & CEO 1956
Mr. Lazarus Krikorian Sr. VP, Chief Accounting Officer & Corp. Controller 1965
Bennett S. Murphy Sr. VP of Investor Relations NA
Ms. Kathy H. Gaddes Exec. VP & Chief Compliance Officer 1963
Ms. Elizabeth S. Campbell Exec. VP & Chief Legal Officer 1975
Ms. Silvana Battaglia Exec. VP & Chief HR Officer 1967

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions